Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9259981 | 1.00 | ALOX15 (0.30) | ALOX15 | |
| SCHEMBL835617 | 0.97 | — | — | |
| SCHEMBL693530 | 0.89 | — | — | |
| SCHEMBL19554084 | 0.80 | — | — | |
| SCHEMBL605855 | 0.77 | — | — | |
| SCHEMBL2155057 | 0.76 | — | — | |
| SCHEMBL1676791 | 0.76 | — | — | |
| SCHEMBL2153675 | 0.76 | — | — | |
| SCHEMBL2154219 | 0.76 | — | — | |
| SCHEMBL4652997 | 0.76 | ALOX15 (0.33) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230097871-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4008405-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2022-06-08 | — | — | EP | disclosed |
| CN-114206832-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| US-10172854-B2 | Compositions and methods for treating mitochondrial diseases | BIOVISTA, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180110775-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL DISEASES | BIOVISTA INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-9763939-B2 | Compositions and methods for treating mitochondrial diseases | BIOVISTA, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160213667-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL DISEASES | BIOVISTA INC (US) | 2016-07-28 | — | — | US | disclosed |
| EP-2375900-B1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | BIOVISTA INC (US) | 2016-03-02 | — | — | EP | disclosed |
| WO-2013130422-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL DISEASES | BIOVISTA, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-8497397-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| EP-2375900-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | Biovista, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010068867-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | BIOVISTA, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO COMPANY , LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1908466-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-1880720-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-20060041144-A1 | Phenylpyridine compound and fungicidal compostion containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-02-23 | — | — | US | disclosed |
| US-20050192359-A1 | N-biphenylamides and fungicidal compositions containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | disclosed |
| EP-1541557-A1 | PHENYLPYRIDINE COMPOUND AND BACTERICIDAL COMPOSITION CONTAINING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1486483-A1 | N-BIPHENYLAMIDES AND FUNGICIDAL COMPOSITIONS CONTAINING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PTMS, C1S, ACP3 | ALOX15 3105/4885 |
| US-20230097871-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | LPAR1, LPAR2, LPAR3 | ALOX15 638/4885 |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACR, NAT1, C1S | ALOX15 2002/4885 |
| US-20050192359-A1 | N-biphenylamides and fungicidal compositions containing the same | CBR3, ARNT, CBR1 | ALOX15 2773/4885 |
| US-10172854-B2 | Compositions and methods for treating mitochondrial diseases | MT-ND2, CS, UQCRC2 | ALOX15 1045/4885 |
| US-20180110775-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL DISEASES | MT-ND2, CS, UQCRC2 | ALOX15 1045/4885 |
| US-20060041144-A1 | Phenylpyridine compound and fungicidal compostion containing the same | CBR3, CYP1A1, PAH | ALOX15 3228/4885 |
| US-20160213667-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL DISEASES | MT-ND2, CS, UQCRC2 | ALOX15 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.